Interestingly, when LINC00052 expression is inhibited, ‘Pro-oncogenic action of estradiol_estrogen receptors’ as well as ‘ESR1/ESR2 ratio in breast cancer’ signalling pathways are modulated [20]. The gene discussed is ESR1; the disease is breast cancer.